GlassScriptPhysician profile
Sudeshna Nandi
NPI 1487671319
$5,903.60
in general payments reported to CMS, 2019-2025
47 companies · $684 in 2025
The $684 reported for 2025 was more than what 84% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $390 · 2021: $814 · 2022: $1,259 · 2023: $1,173 · 2024: $1,356 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,162.59 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,145.89 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $854.02 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $660.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $339.58 | 2020-2025 | |
| Amgen INC. | $263.94 | 2019-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $259.46 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $258.64 | 2020-2025 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $211.75 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $192.77 | 2021-2024 | Rexulti |
| Amarin Pharma, INC. | $166.05 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $140.84 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Inspire Medical Systems, INC. | $93.59 | 2024-2025 | Inspire |
| Currax Pharmaceuticals LLC | $93.13 | 2020-2023 | Nexletol |
| Exact Sciences Corporation | $90.35 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $87.06 | 2020-2025 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sudeshna Nandi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.